Fritextsökning
Innehållstyper
-
Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far
Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, ...
-
A new malaria vaccine offers hope but much more research is still needed
There has long been no vaccine against malaria, but there have been breakthroughs in recent years. However, it is still unclear how we become immune to the mala...
-
Study names with an attitude – more important than you might think
Ironman, T-rex, Star-Trek. Popcorn, Proper, Scout. Nope, these are neither fantasy films nor dog names. They’re the names of ongoing cancer studies in Sweden.
-
The Swedish Life Science Office: “We lost in both coordination and manpower”
Since the turn of the year, the Swedish government’s life science office has operated at a lower capacity. Life Science Sweden has spoken to Pontus Holm, Depart...
-
Marie Gårdmark: Finally, it’s time for a revision of the EU pharma legislation
A challenge for the EU Commission is to deliver a new framework that will also take care of another “pillar” of the pharmaceutical strategy, namely, to ensure that new medicines will be available for all citizens in Europe, writes Marie Gårdmark...
-
Investments worth 40 billion in the Öresund region – “A huge investment wave”
A new report reveals that medical companies in the Oresund region are investing like never before.
-
This is the future location of the new national innovation cluster
Mölndal and Goco Health Innovation City will be the site of a new national innovation cluster for advanced therapies. The business community and the Swedish gov...
-
Företag i Kanada får börja tillverka kokain
Ett företag i den kanadensiska provinsen British Columbia har fått tillstånd att tillverka och sälja kokain på licens.
-
Elypta awarded one million USD from the Star Trek creator’s foundation
Swedish company Elypta, which develops methods for early cancer detection, has been awarded one million USD from an unexpected source: a foundation set up in me...
-
Anna Törner: “My quantified life”
“The expression ‘you can’t see the forest for the trees’ feels newly relevant in the context of wearables. One can easily get caught up in the idea that the mor...
-
Helena Strigård: The rise of the community
Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.
-
Norway finds its path in life science
The life science sector in Norway is on the rise.
-
Automated opening and closing of sample vials
From technical requirements to a suitable solution
-
Synact nådde inte målen i studie: ”Vi är besvikna”
Lundbaserade Synact Pharma nådde inte sitt primära mål i fas IIb-studien Expand, där läkemedelskandidaten resomelagon utvärderades för patienter med svår aktiv ...
-
Setback for pharmaceutical companies in the Zantac case
A Delaware judge has ruled in favour of allowing expert witnesses to testify in a case involving the now-cancelled drug Zantac and its potential carcinogenicity.
-
Anna Törner: To kill your darlings
Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of excit...
-
The stomach medication that became the biggest blockbuster of the 1990s
The omeprazole molecule was synthesised as early as 1979, but it took many years before the then Astra had an approved pharmaceutical. Once this happened, a tab...
-
Zelmic
-
Medicon Valley Alliance
-
USA:s regering skrotar vaccinavtal med Moderna
Trumpadministrationen har avbrutit ett kontrakt som tilldelats Moderna för den sena utvecklingsfasen av ett fågelinfluensavaccin för människor, samt rätten att ...
-
Novo Nordisk invests billions in expanding its production capacity
Danish pharmaceutical company Novo Nordisk is making a major investment to develop and expand its production facility in Hillerød, north of Copenhagen. DKK 15.9...
-
A billion-dollar acquisition makes Novo Nordisk even bigger in obesity
Danish pharmaceutical giant Novo Nordisk acquires Montreal-based Inversago Pharma, which develops treatments for obesity and diabetes.
-
“I am driven by the desire to develop a product that can be sold worldwide”
Ranked number one in the world by the WHO in diarrhoea research and soon in phase III studies for its vaccine candidate – Scandinavian Biopharma is rushing forw...
-
Editorial: ”AI that both impresses and frightens”
”In the past, I've rarely been particularly impressed by something that was produced by AI. But this is something completely different”, Samuel Lagercrantz writ...